Imperial Oil Limited Common Stock vs Viatris Inc — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Viatris Inc trades at $17.56 (market cap $19.81B). The key difference: Imperial Oil Limited Common Stock is far larger — about 3.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| IMO | VTRS | |
|---|---|---|
Market Cap | $62.22B | $19.81B |
Volume | 560,544 | 7,547,542 |
Sector | Energy | Health |
52-Week High | $138.33 | $18.27 |
52-Week Low | $83.72 | $9.98 |
Enterprise Value | $63.13B | $31.92B |
Dividend Yield | 1.9% | 2.78% |
Typical Hold Time | — | 57 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.
Trailing returns across standard periods
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →